Letters to the Editor

A phase II study of post-remission therapy with pembrolizumab in older patients with acute myeloid leukemia

Department of Medicine, Division of Hematology/Oncology, University of Pittsburgh School of Medicine, Pittsburgh PA; UPMC Hillman Cancer Center
UPMC Hillman Cancer Center
UPMC Hillman Cancer Center
UPMC Hillman Cancer Center
Department of Medicine, Division of Hematology/Oncology, University of Pittsburgh School of Medicine, Pittsburgh PA; UPMC Hillman Cancer Center
Department of Medicine, Division of Hematology/Oncology, University of Pittsburgh School of Medicine, Pittsburgh PA; UPMC Hillman Cancer Center
Department of Medicine, Division of Hematology/Oncology, University of Pittsburgh School of Medicine, Pittsburgh PA; UPMC Hillman Cancer Center
UPMC Hillman Cancer Center
UPMC Hillman Cancer Center
UPMC Hillman Cancer Center
UPMC Hillman Cancer Center
Department of Biostatistics, University of Pittsburgh School of Public Health
UPMC Hillman Cancer Center, Pittsburgh, PA; Department of Pathology, University of Pittsburgh School of Medicine
Immunologic Monitoring and Cellular Products Laboratory, UPMC Hillman Caner Center
Department of Medicine, Division of Hematology/Oncology, University of Pittsburgh School of Medicine
Haematologica Early view Aug 8, 2024 https://doi.org/10.3324/haematol.2024.285313